部長・リウマチ膠原病センター長 岡田　正人

• 医師一覧

• 主な経歴

  Beth Israel Medical Center in New York　内科研修

  米国Yale University リウマチ膠原病内科　後期研修

  米国Yale Universityアレルギー臨床免疫科　後期研修

  米国Yale University リウマチ膠原病内科　助手

  仏国パリアメリカンホスピタル　セクションチーフ

• 主な資格

  米国内科専門医

  米国リウマチ膠原病内科専門医

  米国アレルギー臨床免疫科専門医（成人、小児）

  日本リウマチ学会専門医、指導医

  日本内科学会総合内科専門医

  日本アレルギー学会専門医、指導医

• 主な受賞

  Yale Markey‘s Physician Scientist Award （イェール大学）

  米国リウマチ学会 Senior Rheumatology Scholar Award

• 主な教育活動

  東京大学医科学研究所附属病院非常勤講師

  京都大学大学院非常勤講師

  大分大学非常勤講師

  愛知医科大学客員教授

• 専門領域

  全身性エリテマトーデス、　ループス腎炎

  膠原病、膠原病関連肺高血圧症

  関節リウマチ

• 対応可能言語

  日本語、英語

• 主な学会活動

  日本臨床リウマチ学会：理事

  日本リウマチ学会：評議員

  GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis)

  欧州SLE学会（European Lupus Society)

  ACP、ACR、AAAAI、EAACI

• 論文情報

  ※この表はスクロールします

  発表年	雑誌名・巻・頁	論題	発表者
  2021	PloS one, 16(1), e0245954.	LOOP, a cross-sectional, observational study investigating the clinical specialty setting as a determinant of disease management in psoriatic arthritis: Subgroup analysis results from Japan.	Okada, M., Kurimoto, S., Ganz, F., & Boehncke, W. H.
  2020	Journal of the European Academy of Dermatology and Venereology, 34(9), 2035-2043.	Association between clinical specialty setting and disease management in patients with psoriatic arthritis: results from LOOP, a cross‐sectional, multi‐country, observational study.	Boehncke, W. H., Horváth, R., Dalkiliç, E., Lima, S. A. L., Okada, M., Hojnik, M., ... & Lubrano, E.
  2020	Clinical rheumatology, 1-5.	Validation of the 2019 ACR/EULAR classification criteria of systemic lupus erythematosus in 100 Japanese patients: a real-world setting analysis.	Suda, M., Kishimoto, M., Ohde, S., & Okada, M.
  2020	American Journal of Roentgenology, 215(2), 406-412.	CT findings of upper urinary tract lesions in IgG4-related disease: comparison with urothelial carcinoma.	Kamo, M., Nozaki, T., Muraishi, N., Hattori, K., Suzuki, K., Okada, M., & Yamamura, J.
  2020	Annals of the rheumatic diseases, 79(10), 1310-1319.	Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52.	Smolen, J. S., Mease, P., Tahir, H., Schulze-Koops, H., de la Torre, I., Li, L., ... & Nash, P.
  2020	Clinical Rheumatology, 39(12), 3653-3659.	Potential and prognostic factor for belimumab-free remission in patients with systemic lupus erythematosus: a single-center retrospective analysis.	Nakai, T., Fukui, S., Ikeda, Y., Shimizu, H., Tamaki, H., & Okada, M.
  2018	Clinical rheumatology, 1-8.	Safety and efficacy of alternate-day corticosteroid treatment as adjunctive therapy for rheumatoid arthritis: a comparative study.	Suda, M., Ohde, S., Tsuda, T., Kishimoto, M., & Okada, M.
  2018	International journal of rheumatic diseases, 21(5), 975-981.	Effects of quality indicator monitoring for glucocorticoid‐induced osteoporosis and trends of drug treatment in a Japanese hospital.	Suda, M., Suyama, Y., Ohde, S., Tsuda, T., Sawada, H., Kishimoto, M., & Okada, M.
  2018	Archives of rheumatology, 33(3), 302.	Mizoribine is as Effective as Methotrexate for the Treatment of Polymyalgia Rheumatica: A Retrospective Case Series Analysis.	Shiraishi, K., Masei, S. U. D. A., Rokutanda, R., Kishimoto, M., & Okada, M.
  2018	PloS one, 13(4), e0196009.	Effect of plasma exchange on in-hospital mortality in patients with pulmonary hemorrhage secondary to antineutrophil cytoplasmic antibody-associated vasculitis: A propensity-matched analysis using a nationwide administrative database.	Uechi, E., Okada, M., & Fushimi, K.
  2018	Rheumatology international, 38(10), 1825-1831.	Concomitant use of intravenous methylprednisolone to increase retention rate of abatacept in rheumatoid arthritis.	Sawada, H., Suda, M., Rokutanda, R., Kobayashi, D., Mitsumasa, K., & Okada, M.
  2017	Arthritis & Rheumatology, 69(5), 1016-1027.	Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty‐Two-Week Randomized, Double‐Blind, Placebo‐Controlled Study.	Stohl, W., Schwarting, A., Okada, M., Scheinberg, M., Doria, A., Hammer, A. E., ... & Roth, D.
  2017	The Lancet.	Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial.	Nash, P., Kirkham, B., Okada, M., Rahman, P., Combe, B., Burmester, G. R., ... & Genovese, M.
  2017	Journal of the American Academy of Dermatology.	Nail findings in patients with psoriatic arthritis: A cross-sectional study with special reference to transverse grooves.	Zenke, Y., Ohara, Y., Kobayashi, D., Arai, S., Kishimoto, M., Okada, M., & Eto, H.
  2016	臨床検査, 60(7), 698-702.	SLE 診療の変遷.	北田彩子, 岡田正人
  2016	Annals of the rheumatic diseases, annrheumdis-2016.	Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1.	Mease, P. J., van der Heijde, D., Ritchlin, C. T., Okada, M., Cuchacovich, R. S., Shuler, C. L., ... & Gladman, D. D.
  2016	Modern rheumatology, 26(4), 557-561.	Safety and efficacy of upfront graded administration of trimethoprim-sulfamethoxazole in systemic lupus erythematosus: A retrospective cohort study.	Suyama, Y., Okada, M., Rokutanda, R., Min, C., Sassé, B., Kobayashi, D., ... & Kishimoto, M.
  2014	medicina, 51(12), 2113-2118.	全身性エリテマトーデス	岡田正人
  2014	Rheumatology international, 34(5), 643-647.	Prolongation of heart rate-corrected QT interval is a predictor of cardiac autonomic dysfunction in patients with systemic lupus erythematosus.	Nomura, A., Kishimoto, M., Takahashi, O., Deshpande, G. A., Yamaguchi, K., & Okada, M.
  2013	The Journal of dermatology, 40(2), 94-97.	Experience with the use of hydroxychloroquine for the treatment of lupus erythematosus.	Momose, Y., Arai, S., Eto, H., Kishimoto, M., & Okada, M.
  2012	Lupus, 21(13), 1444-1449.	Efficacy and safety of multitarget therapy with mizoribine and tacrolimus for systemic lupus erythematosus with or without active nephritis.	Nomura, A., Shimizu, H., Kishimoto, M., Suyama, Y., Rokutanda, R., Ohara, Y., ... & Okada, M.